Dr. Julien Caumartin holds a PhD in immunology from the University of Paris Diderot (France) and joined Invectys in 2013 after two postdocs at the Scripps Research Institute (USA) and at CEA Fontenay-aux-Roses (France), and two years at Intellectys as Senior Scientist.
He demonstrated that membrane transfers (trogocytosis) and anchored HLA-G proteins between tumor cells and effector cells induced a tolerogenic microenvironment (2006) and suppressive Natural Killer cells (2007). He also identified that iNKT cells could be used as therapeutic adjuvant for vaccination (2009). He demonstrated that Prion disease replicate in peripheral immune system (2010). He developed new methods to induce new anti-HLA-G antibodies (2012) and identified new blocking antibodies against HLA-G (2016) and demonstrated functionality of anti-HLA-G CAR-T cells (2018, 2019).
